HighTower Advisors’s PLx Pharma Inc. Common Stock PLXP Stock Holding History

HighTower Advisors’s Portfolio PLXP Stock Details PLXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-26,507	Closed	-$3K	–	3803
2023 Q1	$3K	Hold	26,507	–	–	﹤0.01%	3265
2022 Q4	$4K	Sell	26,507 -3,250	-11%	-$1.36K	﹤0.01%	3232
2022 Q3	$19K	Hold	29,757	–	–	﹤0.01%	2978
2022 Q2	$73K	Sell	29,757 -3,000	-9%	-$8.34K	﹤0.01%	2851
2022 Q1	$131K	Buy	32,757 +11,682	+55%	+$64K	﹤0.01%	2934
2021 Q4	$169K	Sell	21,075 -2,334	-10%	-$27.4K	﹤0.01%	2827
2021 Q3	$452K	Buy	+23,409	New	+$409K	﹤0.01%	2117

Other funds holding PLXP

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

BBA

Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return

HighTower Advisors's PLXP Position: Q2 2023 in Review

HighTower Advisors sold out of PLx Pharma Inc. Common Stock (PLXP) in Q2 2023, closing a stake of 26,507 shares — an estimated $3K sold.

HighTower Advisors first reported a position in PLXP in Q3 2021 and held it in 7 quarters. The position peaked at $452K in Q3 2021. 4 funds tracked by Wall St. Rank hold PLXP as of Q2 2023.

HighTower Advisors reported no remaining PLx Pharma Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
HighTower Advisors sold 26,507 PLx Pharma Inc. Common Stock shares in Q2 2023, an estimated $3K.
HighTower Advisors first reported a position in PLx Pharma Inc. Common Stock in Q3 2021 and held it in 7 quarters.
HighTower Advisors's PLx Pharma Inc. Common Stock position peaked at $452K in Q3 2021.
4 funds tracked by Wall St. Rank held PLx Pharma Inc. Common Stock as of Q2 2023.

Based on HighTower Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.